Clougherty, Jane E.Kinnee, Ellen J.Cardet, Juan CarlosMauger, DavidBacharier, LeonardBeigelman, AvrahamBlake, Kathryn V.Cabana, Michael D.Castro, MarioChmiel, James F.Covar, RoninaFitzpatrick, AnneGaffin, Jonathan M.Gentile, DeborahIsrael, ElliotJackson, Daniel J.Kraft, MonicaKrishnan, Jerry A.Kumar, Harsha VardhanLang, Jason E.Lazarus, Stephen C.Lemanske, Robert F.Lima, JohnMartinez, Fernando D.Morgan, WayneMoy, JamesMyers, RossNaureckas, Edward T.Ortega, Victor E.Peters, Stephen P.Phipatanakul, WandaPongracic, Jacqueline ARoss, KristieSheehan, William J.Smith, Lewis J.Solway, JulianSorkness, Christine A.Wechsler, Michael E.Wenzel, SallyWhite, Steven R.Holguin, Fernando2021-04-292021-04-292021Clougherty, J. E., Kinnee, E. J., Cardet, J. C., Mauger, D., Bacharier, L., Beigelman, A., ... & Holguin, F. (2021). Geography, generalisability, and susceptibility in clinical trials. The Lancet Respiratory Medicine, 9(4), 330-332. https://doi.org/10.1016/S2213-2600(21)00046-1https://hdl.handle.net/1805/25811This article is made available for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.enPublic Health Emergencyrandomised clinical trialsCOVID-19geographyArticle